EICHOR
● Recruiting
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Condition: Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
About this study
The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lacutoclax is a potent and selective BCL-2 inhibitor with relatively weaker inhibitory activity against BCL-XL and BCL-W. Preliminary clinical data have demonstrated promising efficacy and an acceptable safety profile in patients with CLL/SLL and other B-cell non-Hodgkin lymphomas (B-NHLs). This is an open-label, single-arm, multicenter Phase II study evaluating the efficacy and safety of oral Lacutoclax tablets in patients with relapsed or refractory CLL/SLL.
This description comes directly from the study's public registry record.
Talk to the study team
Jianyong Li · 025-83781120 · lijianyonglm@126.com
Always discuss trial participation with your own doctor first.
Locations (1)
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07609823